MedTrace Logo

Ketamine Infusion for Social Anxiety Disorder

NCT02083926 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-03-18

Study results available
· View outcomes & findings →

Summary

* Social Anxiety Disorder (SAD) is common and causes significant impairment.
* First-line treatments for Social Anxiety Disorder are only partially effective. Many SAD patients experience little or inadequate symptom relief with available treatments.
* Ketamine is a potent NMDA receptor antagonist. Ketamine represents an agent with a potentially novel mechanism of action for the treatment of anxiety disorders.
* Ketamine has demonstrated efficacy in the treatment of psychiatric disorders closely related to Social Anxiety Disorder including Major Depression, Bipolar Depression and possibly Obsessive-Compulsive Disorder.

Ketamine represents the possibility to provide rapid symptom relief to patients with SAD and may provide the mechanism for future drug development to treat SAD more rapidly and effectively.

Conditions

Interventions

DRUG

Ketamine

Ketamine (a single 0.5mg/kg intravenously over 40 minutes).

OTHER

Saline

Saline (a single 0.5mg/kg intravenously over 40 minutes).

Sponsors & Collaborators

  • Patterson Trust Mentored Research Award: Clinical, Health Services and Policy Research

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Michael H. Bloch, MD, MS · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-02
Primary Completion
2016-09-27
Completion
2016-09-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02083926 on ClinicalTrials.gov